Treatment for radiation retinopathy of uveal melanoma undergone radiotherapy: the current situation_Chinese Journal of Ocular Fundus Diseases

Authors：

Chen Mengxi , Liu Yueming ,  Wei Wenbin

Beijing Tongren Eye Center, Beijing key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology&Visual Sciences Key Lab, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China;

Corresponding author：

Wei Wenbin, Email: weiwenbintr@163.com

Keywords：

Uveal neoplasms/radiotherapy; Radiotherapy/adverse effects; Retinal diseases/therapy; Review

DOI：

10.3760/cma.j.issn.1005-1015.2018.05.025

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Radiotherapy is the prior treatment for uveal melanoma, but a major problem confronted most of the patients is radiation retinopathy, which accompanied with severe visual loss and secondary enucleation potential. There is no optium choice and normative strategy so far, the intraocular melanoma society has focused on application of anti-vascular endothelial growth factor drugs injection and glucocorticoids. This article reviews a series of potential managements for radiation retinopathy and its further stage .

Citation： Chen Mengxi, Liu Yueming, Wei Wenbin. Treatment for radiation retinopathy of uveal melanoma undergone radiotherapy: the current situation. Chinese Journal of Ocular Fundus Diseases, 2018, 34(5): 515-518. doi: 10.3760/cma.j.issn.1005-1015.2018.05.025 Copy

1.	王光璐, 魏文斌, 蔡善钰, 等. 脉络膜黑色素瘤敷贴放射治疗的初步观察[J]. 中华眼底病杂志, 2006, 22(3):157-160.Wang GL, Wei WB, Cai SY, et al.Priliminary observation on choroidal melanoma treated by plaque radiotherapy[J]. Chin J Ocul Fundus Dis, 2006, 22(3):157-160.
2.	Melia BM, Abramson DH, Albert DM, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. Visual acuity after 3 years COMS report no.16[J]. Ophthalmology, 2001, 108(2): 348-366.
3.	Matet A, Daruich A, Zografos L. Radiation maculopathy after proton beam therapy for uveal melanoma: optical coherence tomography angiography alterations influencing visual acuity[J]. Invest Ophthalmol Vis Sci, 2017, 58(10):3851-3861.DOI: 10.1167/iovs.17-22324.
4.	Bianciotto C, Shields CL, Pirondini C. Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma[J]. Ophthalmology, 2010, 117(5):1005-1012. DOI: 10.1016/j.ophtha.2009.10.015.
5.	Horgan N, Shields CL, Mashayekhi A, et al.Classification and treatment of radiation maculopathy[J]. Curr Opin Ophthalmol, 2010, 21(3):233-238. DOI: 10.1097/ICU.0b013e3283386687.
6.	Horgan N, Shields CL, Mashayekhi A, et al.Early macular morphological changes following plaque radiotherapy for uveal melanoma[J]. Retina, 2008, 28(2):263-273.
7.	Bianciotto C, Shields CL, Pirondini C, et al.Vitreous hemorrhage after plaque radiotherapy for uveal melanoma[J]. Retina, 2012, 32(6):1156-1164.DOI:10.1097/IAE.0b013e3182340cc1.
8.	Kinyoun JL.Long-term visual acuity results of treated and untreated radiation retinopathy (an AOS thesis)[J]. Trans Am Ophthalmol Soc, 2008, 106:325-335.
9.	Materin MA, Bianciotto CG, Wu C, et al.Sector laser photocoagulation for the prevention of macular edema after plaque radiotherapy for uveal melanoma: a pilot study[J]. Retina, 2012, 32(8):1601-1607.DOI: 10.1097/IAE.0b013e3182437e70.
10.	Shah NV, Houston SK, Markoe AM, et al.Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity[J]. Clin Ophthalmol, 2012, 6:1739-1748.DOI: 10.2147/OPTH.S34949.
11.	Finger PT, Chin KJ, Semenova EA. Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study[J]. Eur J Ophthalmol, 2016, 26(1):60-66. DOI: 10.5301/ejo.5000670.
12.	Reichstein D.Current treatments and preventive strategies for radiation retinopathy[J]. Curr Opin Ophthalmol, 2015, 26(3):157-166.DOI: 10.1097/ICU.0000000000000141.
13.	Mahdjoubi A, Najean M, Lemaitre S, et al. Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy[J]. Graefe’s Arch Clin Exp Ophthalmol, 2018, 256(2):411-420.DOI:10.1007/s00417-017-3834-3.
14.	Hurtikova K, Gerding H.Combined laser photocoagulation and anti-VEGF injection treatment in radiation retinopathy[J]. Klin Monbl Augenheilkd, 2017, 234(5): 515-519.DOI:10.1055/s-0042-123165.
15.	Shields CL, Demirci H, Dai V, et al. Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma[J]. Retina, 2005, 25 (7): 868-874.
16.	Shah NV, Houston SK, Markoe A, et al.Combination therapy with triamcinolone acetonide and bevacizumab for the treatment of severe radiation maculopathy in patients with posterior uveal melanoma[J]. Clin Ophthalmol, 2013, 7:1877-1882. DOI: 10.2147/OPTH.S47684.
17.	Bui KM, Chow CC, Mieler WF. Treatment of recalcitrant radiation maculopathy using intravitreal dexamethasone (Ozurdex) implant[J]. Retin Cases Brief Rep, 2014, 8(3): 167- 170.DOI: 10.1097/ICB.0000000000000032.
18.	Frizziero L, Parrozzani R, Trainiti S, et al. Intravitreal dexamethasone implant in radiation-induced macular oedema[J]. Br J Ophthalmol, 2017, 101(12):1699-1703. DOI: 10.1136/bjophthalmol-2017-310220.
19.	Russo A, Reibaldi M, Avitabile T, et al. Dexamethasone intravitreal implant vs ranibizumab in the treatment of macular edema secondary to brachytherapy for choroidal melanoma[J/OL]. Retina, 2017, 2017:E1[2017-03-07]. https://insights.ovid.com/pubmed?pmid=28272283. DOI:10.1097/IAE.0000000000001585.[published online ahead of print].
20.	Caminal JM, Flores-Moreno I, Arias L, et al. Intravitreal dexamethasone implant for radiation maculopathy secondary to plaque brachytherapy in choroidal melanoma[J]. Retina, 2015, 35(9):1890-1897.DOI:10.1097/IAE.0000000000000537.
21.	Koc I, Kadayifcilar S, Kiratli H, et al. Intravitreal dexamethasone (Ozurdex) implant for radiation maculopathy secondary to stereotactic radiotherapy for posterior uveal melanoma[J/OL]. Retin Cases Brief Rep, 2017, 2017:E1[2017-05-09]. https://insights.ovid.com/pubmed?pmid=28489707. DOI: 10.1097/ICB.0000000000000593.[published online ahead of print].
22.	Finger PT. Radiation retinopathy is treatable with antivascular endothelial growth factor bevacizumab (Avastin)[J]. Int J Radiat Oncol Biol Phys, 2008, 70(4):974-977. DOI: 10.1016/j.ijrobp.2007.11.045.
23.	Seibel I, Hager A, Riechardt AI, et al. Antiangiogenic or corticosteroid treatment in patients with radiation maculopathy after proton beam therapy for uveal melanoma[J]. Am J Ophthalmol, 2016, 168:31-39.DOI: 10.1016/j.ajo.2016.04.024.
24.	Pagliara MM, Tagliaferri L, Azario L, et al. Ruthenium brachytherapy for uveal melanomas: factors affecting the development of radiation complications[J]. Brachytherapy, 2018, 17(2):432-438.DOI: 10.1016/j.brachy.2017.11.004.
25.	Mashayekhi A, Schönbach E, Shields CL, et al. Early subclinical macular edema in eyes with uveal melanoma: association with future cystoid macular edema[J]. Ophthalmology, 2015, 122(5):1023-1029.DOI: 10.1016/j.ophtha.2014.12.034.
26.	Bakri SJ, Larson TA.The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy[J]. Semin Ophthalmol, 2015, 30(4):276-280.DOI:10.3109/08820538.2013.847110.
27.	Chia SN, Smith HB, Hammer HM, et al.Incidence and indications for pars plana vitrectomy following the treatment of posterior uveal melanomas in Scotland[J]. Eye (Lond), 2015, 29(6):748-756.DOI: 10.1038/eye.2015.20.
28.	Mccannel TA, Kamrava M, Demanes J, et al. 23-mm iodine-125 plaque for uveal melanoma: benefit of vitrectomy and silicone oil on visual acuity[J]. Graefe’s Arch Clin Exp Ophthalmol, 2016, 254(12):2461-2467.DOI:10.1007/s00417-016-3485-9.
29.	Riechardt AI, Cordini D, Rehak M, et al. Trabeculectomy in patients with uveal melanoma after proton beam therapy[J]. Graefe’s Arch Clin Exp Ophthalmol, 2016, 254 (7):1379-1385. DOI:10.1007/s00417-016-3310-5.
30.	Horgan N, Shields CL, Mashayekhi A, et al. Periocular triamcinolone for prevention of macular edema after iodine 125 plaque radiotherapy of uveal melanoma[J]. Retina, 2008, 28(7):987-995.DOI: 10.1097/IAE.0b013e31816b3192.
31.	Horgan N, Shields CL, Mashayekhi A, et al. Periocular triamcinolone for prevention of macular edema after plaque radiotherapy of uveal melanoma: a randomized controlled trial[J]. Ophthalmology, 2009, 116(7):1383-1390.DOI:10.1016/j.ophtha.2009.01.051.
32.	Shah SU, Shields CL, Bianciotto CG, et al.Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma[J]. Ophthalmology, 2014, 121(1):269-275. DOI:10.1016/j.ophtha.2013.08.039.
33.	Haji Mohd Yasin NA, Gray AR, Bevin TH, et al. Choroidal melanoma treated with stereotactic fractionated radiotherapy and prophylactic intravitreal bevacizumab: the Dunedin hospital experience[J]. J Med Imag Health In, 2016, 60(6):756-763.
34.	Li J, Cui Y, Wang Q, et al. The proliferation of malignant melanoma cells could be inhibited by ranibizumab via antagonizing VEGF through VEGFR1[J]. Mol Vis, 2014, 20(236):649-660.
35.	Krema H, Somani S, Sahgal A, et al. Stereotactic radiotherapy for treatment of juxtapapillary choroidal melanoma: 3-year follow-up[J]. Br J Ophthalmol, 2009, 93(9):1172- 1176.DOI: 10.1136/bjo.2008.153429.
36.	Oliver SC, Leu MY, Demarco JJ, et al. Attenuation of iodine 125 radiation with vitreous substitutes in the treatment of uveal melanoma[J]. Arch Ophthalmol, 2010, 128(7):888-893. DOI:10.1001/archophthalmol.2010.117.
37.	Mccannel TA, Mccannel CA. Iodine 125 brachytherapy with vitrectomy and silicone oil in the treatment of uveal melanoma: 1-to-1 matched case-control series[J]. Int J Radiat Oncol Biol Phys, 2014, 89(2):347-352.DOI: 10.1016/j.ijrobp.2014.02.021.
38.	Aziz HA, Singh N, Bena J, et al. Vision loss following episcleral brachytherapy for uveal melanoma: development of a vision prognostication tool[J]. JAMA Ophthalmol, 2016, 134(6): 615-620.DOI:10.1001/jamaophthalmol.2016.0104.

1. 王光璐, 魏文斌, 蔡善钰, 等. 脉络膜黑色素瘤敷贴放射治疗的初步观察[J]. 中华眼底病杂志, 2006, 22(3):157-160.Wang GL, Wei WB, Cai SY, et al.Priliminary observation on choroidal melanoma treated by plaque radiotherapy[J]. Chin J Ocul Fundus Dis, 2006, 22(3):157-160.
2. Melia BM, Abramson DH, Albert DM, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. Visual acuity after 3 years COMS report no.16[J]. Ophthalmology, 2001, 108(2): 348-366.
3. Matet A, Daruich A, Zografos L. Radiation maculopathy after proton beam therapy for uveal melanoma: optical coherence tomography angiography alterations influencing visual acuity[J]. Invest Ophthalmol Vis Sci, 2017, 58(10):3851-3861.DOI: 10.1167/iovs.17-22324.
4. Bianciotto C, Shields CL, Pirondini C. Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma[J]. Ophthalmology, 2010, 117(5):1005-1012. DOI: 10.1016/j.ophtha.2009.10.015.
5. Horgan N, Shields CL, Mashayekhi A, et al.Classification and treatment of radiation maculopathy[J]. Curr Opin Ophthalmol, 2010, 21(3):233-238. DOI: 10.1097/ICU.0b013e3283386687.
6. Horgan N, Shields CL, Mashayekhi A, et al.Early macular morphological changes following plaque radiotherapy for uveal melanoma[J]. Retina, 2008, 28(2):263-273.
7. Bianciotto C, Shields CL, Pirondini C, et al.Vitreous hemorrhage after plaque radiotherapy for uveal melanoma[J]. Retina, 2012, 32(6):1156-1164.DOI:10.1097/IAE.0b013e3182340cc1.
8. Kinyoun JL.Long-term visual acuity results of treated and untreated radiation retinopathy (an AOS thesis)[J]. Trans Am Ophthalmol Soc, 2008, 106:325-335.
9. Materin MA, Bianciotto CG, Wu C, et al.Sector laser photocoagulation for the prevention of macular edema after plaque radiotherapy for uveal melanoma: a pilot study[J]. Retina, 2012, 32(8):1601-1607.DOI: 10.1097/IAE.0b013e3182437e70.
10. Shah NV, Houston SK, Markoe AM, et al.Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity[J]. Clin Ophthalmol, 2012, 6:1739-1748.DOI: 10.2147/OPTH.S34949.
11. Finger PT, Chin KJ, Semenova EA. Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study[J]. Eur J Ophthalmol, 2016, 26(1):60-66. DOI: 10.5301/ejo.5000670.
12. Reichstein D.Current treatments and preventive strategies for radiation retinopathy[J]. Curr Opin Ophthalmol, 2015, 26(3):157-166.DOI: 10.1097/ICU.0000000000000141.
13. Mahdjoubi A, Najean M, Lemaitre S, et al. Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy[J]. Graefe’s Arch Clin Exp Ophthalmol, 2018, 256(2):411-420.DOI:10.1007/s00417-017-3834-3.
14. Hurtikova K, Gerding H.Combined laser photocoagulation and anti-VEGF injection treatment in radiation retinopathy[J]. Klin Monbl Augenheilkd, 2017, 234(5): 515-519.DOI:10.1055/s-0042-123165.
15. Shields CL, Demirci H, Dai V, et al. Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma[J]. Retina, 2005, 25 (7): 868-874.
16. Shah NV, Houston SK, Markoe A, et al.Combination therapy with triamcinolone acetonide and bevacizumab for the treatment of severe radiation maculopathy in patients with posterior uveal melanoma[J]. Clin Ophthalmol, 2013, 7:1877-1882. DOI: 10.2147/OPTH.S47684.
17. Bui KM, Chow CC, Mieler WF. Treatment of recalcitrant radiation maculopathy using intravitreal dexamethasone (Ozurdex) implant[J]. Retin Cases Brief Rep, 2014, 8(3): 167- 170.DOI: 10.1097/ICB.0000000000000032.
18. Frizziero L, Parrozzani R, Trainiti S, et al. Intravitreal dexamethasone implant in radiation-induced macular oedema[J]. Br J Ophthalmol, 2017, 101(12):1699-1703. DOI: 10.1136/bjophthalmol-2017-310220.
19. Russo A, Reibaldi M, Avitabile T, et al. Dexamethasone intravitreal implant vs ranibizumab in the treatment of macular edema secondary to brachytherapy for choroidal melanoma[J/OL]. Retina, 2017, 2017:E1[2017-03-07]. https://insights.ovid.com/pubmed?pmid=28272283. DOI:10.1097/IAE.0000000000001585.[published online ahead of print].
20. Caminal JM, Flores-Moreno I, Arias L, et al. Intravitreal dexamethasone implant for radiation maculopathy secondary to plaque brachytherapy in choroidal melanoma[J]. Retina, 2015, 35(9):1890-1897.DOI:10.1097/IAE.0000000000000537.
21. Koc I, Kadayifcilar S, Kiratli H, et al. Intravitreal dexamethasone (Ozurdex) implant for radiation maculopathy secondary to stereotactic radiotherapy for posterior uveal melanoma[J/OL]. Retin Cases Brief Rep, 2017, 2017:E1[2017-05-09]. https://insights.ovid.com/pubmed?pmid=28489707. DOI: 10.1097/ICB.0000000000000593.[published online ahead of print].
22. Finger PT. Radiation retinopathy is treatable with antivascular endothelial growth factor bevacizumab (Avastin)[J]. Int J Radiat Oncol Biol Phys, 2008, 70(4):974-977. DOI: 10.1016/j.ijrobp.2007.11.045.
23. Seibel I, Hager A, Riechardt AI, et al. Antiangiogenic or corticosteroid treatment in patients with radiation maculopathy after proton beam therapy for uveal melanoma[J]. Am J Ophthalmol, 2016, 168:31-39.DOI: 10.1016/j.ajo.2016.04.024.
24. Pagliara MM, Tagliaferri L, Azario L, et al. Ruthenium brachytherapy for uveal melanomas: factors affecting the development of radiation complications[J]. Brachytherapy, 2018, 17(2):432-438.DOI: 10.1016/j.brachy.2017.11.004.
25. Mashayekhi A, Schönbach E, Shields CL, et al. Early subclinical macular edema in eyes with uveal melanoma: association with future cystoid macular edema[J]. Ophthalmology, 2015, 122(5):1023-1029.DOI: 10.1016/j.ophtha.2014.12.034.
26. Bakri SJ, Larson TA.The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy[J]. Semin Ophthalmol, 2015, 30(4):276-280.DOI:10.3109/08820538.2013.847110.
27. Chia SN, Smith HB, Hammer HM, et al.Incidence and indications for pars plana vitrectomy following the treatment of posterior uveal melanomas in Scotland[J]. Eye (Lond), 2015, 29(6):748-756.DOI: 10.1038/eye.2015.20.
28. Mccannel TA, Kamrava M, Demanes J, et al. 23-mm iodine-125 plaque for uveal melanoma: benefit of vitrectomy and silicone oil on visual acuity[J]. Graefe’s Arch Clin Exp Ophthalmol, 2016, 254(12):2461-2467.DOI:10.1007/s00417-016-3485-9.
29. Riechardt AI, Cordini D, Rehak M, et al. Trabeculectomy in patients with uveal melanoma after proton beam therapy[J]. Graefe’s Arch Clin Exp Ophthalmol, 2016, 254 (7):1379-1385. DOI:10.1007/s00417-016-3310-5.
30. Horgan N, Shields CL, Mashayekhi A, et al. Periocular triamcinolone for prevention of macular edema after iodine 125 plaque radiotherapy of uveal melanoma[J]. Retina, 2008, 28(7):987-995.DOI: 10.1097/IAE.0b013e31816b3192.
31. Horgan N, Shields CL, Mashayekhi A, et al. Periocular triamcinolone for prevention of macular edema after plaque radiotherapy of uveal melanoma: a randomized controlled trial[J]. Ophthalmology, 2009, 116(7):1383-1390.DOI:10.1016/j.ophtha.2009.01.051.
32. Shah SU, Shields CL, Bianciotto CG, et al.Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma[J]. Ophthalmology, 2014, 121(1):269-275. DOI:10.1016/j.ophtha.2013.08.039.
33. Haji Mohd Yasin NA, Gray AR, Bevin TH, et al. Choroidal melanoma treated with stereotactic fractionated radiotherapy and prophylactic intravitreal bevacizumab: the Dunedin hospital experience[J]. J Med Imag Health In, 2016, 60(6):756-763.
34. Li J, Cui Y, Wang Q, et al. The proliferation of malignant melanoma cells could be inhibited by ranibizumab via antagonizing VEGF through VEGFR1[J]. Mol Vis, 2014, 20(236):649-660.
35. Krema H, Somani S, Sahgal A, et al. Stereotactic radiotherapy for treatment of juxtapapillary choroidal melanoma: 3-year follow-up[J]. Br J Ophthalmol, 2009, 93(9):1172- 1176.DOI: 10.1136/bjo.2008.153429.
36. Oliver SC, Leu MY, Demarco JJ, et al. Attenuation of iodine 125 radiation with vitreous substitutes in the treatment of uveal melanoma[J]. Arch Ophthalmol, 2010, 128(7):888-893. DOI:10.1001/archophthalmol.2010.117.
37. Mccannel TA, Mccannel CA. Iodine 125 brachytherapy with vitrectomy and silicone oil in the treatment of uveal melanoma: 1-to-1 matched case-control series[J]. Int J Radiat Oncol Biol Phys, 2014, 89(2):347-352.DOI: 10.1016/j.ijrobp.2014.02.021.
38. Aziz HA, Singh N, Bena J, et al. Vision loss following episcleral brachytherapy for uveal melanoma: development of a vision prognostication tool[J]. JAMA Ophthalmol, 2016, 134(6): 615-620.DOI:10.1001/jamaophthalmol.2016.0104.

Previous Article
Outer retinal tubulations

Chinese Journal of Ocular Fundus Diseases

Treatment for radiation retinopathy of uveal melanoma undergone radiotherapy: the current situation

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content